{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:26:41Z","timestamp":1789165601687,"version":"build-2803163510"},"reference-count":91,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Neurosci."],"abstract":"<jats:p>MicroRNA (miRNA) is a non-coding single-stranded small molecule of approximately 21 nucleotides. It degrades or inhibits the translation of RNA by targeting the 3\u2032-UTR. The miRNA plays an important role in the growth, development, differentiation, and functional execution of the nervous system. Dysregulated miRNA expression has been associated with several pathological processes of neurodegenerative disorders, including Huntington\u2019s disease (HD). Recent studies have suggested promising roles of miRNAs as biomarkers and potential therapeutic targets for HD. Here, we review the emerging role of dysregulated miRNAs in HD and describe general biology of miRNAs, their pathophysiological implications, and their potential roles as biomarkers and therapeutic agents.<\/jats:p>","DOI":"10.3389\/fncel.2021.705348","type":"journal-article","created":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T03:56:21Z","timestamp":1628222181000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":41,"title":["MicroRNAs in Huntington\u2019s Disease: Diagnostic Biomarkers or Therapeutic Agents?"],"prefix":"10.3389","volume":"15","author":[{"given":"Xiaoyu","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1034\/j.1399-0004.2003.00157.x","article-title":"Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington\u2019s disease.","volume":"64","author":"Almqvist","year":"2003","journal-title":"Clin. Genet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.bbrc.2017.05.040","article-title":"MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington\u2019s disease.","volume":"488","author":"Ban","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B3","doi-asserted-by":"crossref","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington disease.","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1590\/0004-282x20190092","article-title":"Theory of mind impairment in Huntington\u2019s disease patients and their relatives.","volume":"77","author":"Bayliss","year":"2019","journal-title":"Arq. Neuropsiquiatr."},{"key":"B5","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","article-title":"Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.","volume":"6","author":"Blennow","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.bbrc.2015.08.090","article-title":"Regulation of mitochondrial morphology and cell cycle by microRNA-214 targeting Mitofusin2.","volume":"465","author":"Bucha","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B7","first-page":"36","article-title":"Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.","volume":"48","author":"Caron","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"B8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13023-017-0742-x","article-title":"Down-regulation of miR-9\u2217 in the peripheral leukocytes of Huntington\u2019s disease patients.","volume":"12","author":"Chang","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bbi.2014.09.011","article-title":"Plasma inflammatory biomarkers for Huntington\u2019s disease patients and mouse model.","volume":"44","author":"Chang","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ajhg.2013.05.025","article-title":"miR-196a ameliorates phenotypes of Huntington disease in cell, transgenic mouse, and induced pluripotent stem cell models.","volume":"93","author":"Cheng","year":"2013","journal-title":"Am. J. Hum. Genet."},{"key":"B11","doi-asserted-by":"publisher","first-page":"105311","DOI":"10.1016\/j.nbd.2021.105311","article-title":"Plasma neurofilament light chain predicts cerebellar atrophy and clinical progression in spinocerebellar ataxia.","volume":"153","author":"Coarelli","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/2211536604666150713105606","article-title":"Delayed cell cycle progression in STHdh(Q111)\/Hdh(Q111) Cells, a cell model for huntington\u2019s disease mediated by microRNA-19a, microRNA-146a and microRNA-432.","volume":"4","author":"Das","year":"2015","journal-title":"Microrna"},{"key":"B13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2174\/2211536605666151204111323","article-title":"Heat shock factor 1-regulated miRNAs can target huntingtin and suppress aggregates of mutant huntingtin.","volume":"4","author":"Das","year":"2015","journal-title":"Microrna"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1242\/dev.025080","article-title":"miRNAs are essential for survival and differentiation of newborn neurons but not for expansion of neural progenitors during early neurogenesis in the mouse embryonic neocortex.","volume":"135","author":"De Pietri Tonelli","year":"2008","journal-title":"Development"},{"key":"B15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.phrs.2016.05.005","article-title":"Circulating microRNAs in Huntington\u2019s disease: Emerging mediators in metabolic impairment.","volume":"108","author":"Diez-Planelles","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1242\/dmm.002451","article-title":"Mouse models of Huntington disease: variations on a theme.","volume":"2","author":"Ehrnhoefer","year":"2009","journal-title":"Dis. Model. Mech."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/14712598.2020.1792880","article-title":"AAV5-miHTT gene therapy for Huntington disease: lowering both huntingtins.","volume":"20","author":"Evers","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a huntington\u2019s disease minipig model.","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2165\/11534430-000000000-00000","article-title":"Advances in the pharmacological management of Huntington\u2019s disease.","volume":"70","author":"Frank","year":"2010","journal-title":"Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3233\/jhd-170260","article-title":"Physical therapy and exercise interventions in huntington\u2019s disease: a mixed methods systematic review.","volume":"6","author":"Fritz","year":"2017","journal-title":"J. Huntingtons Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1093\/hmg\/ddr111","article-title":"Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington\u2019s disease.","volume":"20","author":"Gaughwin","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.bbrc.2018.06.034","article-title":"Beta catenin is regulated by its subcellular distribution and mutant huntingtin status in Huntington\u2019s disease cell STHdhQ111\/HdhQ111.","volume":"503","author":"Ghatak","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e23837","DOI":"10.1371\/journal.pone.0023837","article-title":"Regulation of miR-146a by RelA\/NFkB and p53 in STHdh(Q111)\/Hdh(Q111) cells, a cell model of Huntington\u2019s disease.","volume":"6","author":"Ghose","year":"2011","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1177\/1039856218791036","article-title":"Huntington\u2019s disease: Neuropsychiatric manifestations of Huntington\u2019s disease.","volume":"26","author":"Goh","year":"2018","journal-title":"Australas. Psychiatry"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s10072-017-3086-3","article-title":"Secretases-related miRNAs in Alzheimer\u2019s disease: new approach for biomarker discovery.","volume":"38","author":"Hajjari","year":"2017","journal-title":"Neurol. Sci."},{"key":"B26","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/jnc.14852","article-title":"Mutant huntingtin fails to directly impair brain mitochondria.","volume":"151","author":"Hamilton","year":"2019","journal-title":"J. Neurochem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s40265-017-0831-0","article-title":"Deutetrabenazine: a review in chorea associated with huntington\u2019s disease.","volume":"77","author":"Heo","year":"2017","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.7150\/thno.18813","article-title":"miR-196a enhances neuronal morphology through suppressing RANBP10 to provide neuroprotection in huntington\u2019s disease.","volume":"7","author":"Her","year":"2017","journal-title":"Theranostics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e1004188","DOI":"10.1371\/journal.pgen.1004188","article-title":"MicroRNAs located in the Hox gene clusters are implicated in huntington\u2019s disease pathogenesis.","volume":"10","author":"Hoss","year":"2014","journal-title":"PLoS Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fnagi.2016.00036","article-title":"MicroRNA profiles in parkinson\u2019s disease prefrontal cortex.","volume":"8","author":"Hoss","year":"2016","journal-title":"Front. Aging Neurosci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12920-015-0083-3","article-title":"MiR-10b-5p expression in Huntington\u2019s disease brain relates to age of onset and the extent of striatal involvement.","volume":"8","author":"Hoss","year":"","journal-title":"BMC Med. Genomics"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1002\/mds.26457","article-title":"Study of plasma-derived miRNAs mimic differences in Huntington\u2019s disease brain.","volume":"30","author":"Hoss","year":"","journal-title":"Mov. Disord."},{"key":"B33","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1093\/hmg\/ddq063","article-title":"An ovine transgenic Huntington\u2019s disease model.","volume":"19","author":"Jacobsen","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/jnc.12400","article-title":"Presenilin 2 influences miR146 level and activity in microglia.","volume":"127","author":"Jayadev","year":"2013","journal-title":"J. Neurochem."},{"key":"B35","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12017-009-8063-4","article-title":"Gene dysregulation in Huntington\u2019s disease: REST, microRNAs and beyond.","volume":"11","author":"Johnson","year":"2009","journal-title":"Neuromolecular Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e54222","DOI":"10.1371\/journal.pone.0054222","article-title":"MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington\u2019s disease-related mechanisms.","volume":"8","author":"Jovicic","year":"2013","journal-title":"PLoS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"101664","DOI":"10.1016\/j.pneurobio.2019.101664","article-title":"MicroRNA dysregulation in neurodegenerative diseases: a systematic review.","volume":"182","author":"Juzwik","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/cga.12043","article-title":"Human diseases caused by germline and somatic abnormalities in microRNA and microRNA-related genes.","volume":"54","author":"Kawahara","year":"2014","journal-title":"Congenit. Anom."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/ng.3694","article-title":"General rules for functional microRNA targeting.","volume":"48","author":"Kim","year":"2016","journal-title":"Nat. Genet."},{"key":"B40","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-6606-7-46","article-title":"microRNA-128a dysregulation in transgenic Huntington\u2019s disease monkeys.","volume":"7","author":"Kocerha","year":"2014","journal-title":"Mol. Brain"},{"key":"B41","doi-asserted-by":"publisher","first-page":"16999","DOI":"10.3390\/ijms140816999","article-title":"Regulation of huntingtin gene expression by miRNA-137, -214, -148a, and their respective isomiRs.","volume":"14","author":"Kozlowska","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e0162788","DOI":"10.1371\/journal.pone.0162788","article-title":"miR-196a ameliorates cytotoxicity and cellular phenotype in transgenic huntington\u2019s disease monkey neural cells.","volume":"11","author":"Kunkanjanawan","year":"2016","journal-title":"PLoS One"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0190550","DOI":"10.1371\/journal.pone.0190550","article-title":"MicroRNA signatures of endogenous Huntingtin CAG repeat expansion in mice.","volume":"13","author":"Langfelder","year":"2018","journal-title":"PLoS One"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.1371\/journal.pgen.0030135","article-title":"Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism.","volume":"3","author":"Lee","year":"2007","journal-title":"PLoS Genet."},{"key":"B45","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10072-017-2841-9","article-title":"Plasma levels of miR-137 and miR-124 are associated with Parkinson\u2019s disease but not with Parkinson\u2019s disease with depression.","volume":"38","author":"Li","year":"2017","journal-title":"Neurol. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.gpb.2012.07.005","article-title":"MicroRNAs in common human diseases.","volume":"10","author":"Li","year":"2012","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"B47","doi-asserted-by":"publisher","first-page":"786","DOI":"10.4103\/1673-5374.156978","article-title":"MicroRNA-124 slows down the progression of Huntington\u2019s disease by promoting neurogenesis in the striatum.","volume":"10","author":"Liu","year":"2015","journal-title":"Neural. Regen. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s10072-016-2643-5","article-title":"The interplay of microRNAs and post-ischemic glutamate excitotoxicity: an emergent research field in stroke medicine.","volume":"37","author":"Majdi","year":"2016","journal-title":"Neurol. Sci."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1002\/mds.23912","article-title":"Basal ganglia atrophy in prodromal Huntington\u2019s disease is detectable over one year using automated segmentation.","volume":"26","author":"Majid","year":"2011","journal-title":"Mov. Disord."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1038\/mtna.2016.7","article-title":"Design. characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for huntington\u2019s disease.","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"B51","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease.","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene. Ther."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.cell.2006.07.031","article-title":"A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes.","volume":"126","author":"Miranda","year":"2006","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cmet.2019.07.011","article-title":"Extracellular miRNAs: from biomarkers to mediators of physiology and disease.","volume":"30","author":"Mori","year":"2019","journal-title":"Cell Metab."},{"key":"B54","doi-asserted-by":"publisher","first-page":"Rrn1205","DOI":"10.1371\/currents.RRN1205","article-title":"Optimization of an HTRF assay for the detection of soluble mutant huntingtin in human buffy coats: a potential biomarker in blood for huntington disease.","volume":"2","author":"Moscovitch-Lopatin","year":"2010","journal-title":"PLoS Curr."},{"key":"B55","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/2047-9158-3-17","article-title":"In silico analysis of regulatory networks underlines the role of miR-10b-5p and its target BDNF in huntington\u2019s disease.","volume":"3","author":"M\u00fcller","year":"2014","journal-title":"Transl. Neurodegener."},{"key":"B56","doi-asserted-by":"publisher","first-page":"725","DOI":"10.18632\/aging.100603","article-title":"Age-related changes in microRNA levels in serum.","volume":"5","author":"Noren Hooten","year":"2013","journal-title":"Aging"},{"key":"B57","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nrg2100","article-title":"Chromatin crosstalk in development and disease: lessons from REST.","volume":"8","author":"Ooi","year":"2007","journal-title":"Nat. Rev. Genet."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e0220393","DOI":"10.1371\/journal.pone.0220393","article-title":"The interaction between RE1-silencing transcription factor (REST) and heat shock protein 90 as new therapeutic target against Huntington\u2019s disease.","volume":"14","author":"Orozco-Diaz","year":"2019","journal-title":"PLoS One"},{"key":"B59","doi-asserted-by":"publisher","first-page":"14341","DOI":"10.1523\/jneurosci.2390-08.2008","article-title":"The bifunctional microRNA miR-9\/miR-9\u2217 regulates REST and CoREST and is downregulated in Huntington\u2019s disease.","volume":"28","author":"Packer","year":"2008","journal-title":"J. Neurosci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/jad-150451","article-title":"Dysregulation and diagnostic potential of microRNA in Alzheimer\u2019s disease.","volume":"49","author":"Pan","year":"2016","journal-title":"J. Alzheimers. Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1089\/hum.2017.199","article-title":"Artificial miRNAs reduce human mutant huntingtin throughout the striatum in a transgenic sheep model of huntington\u2019s disease.","volume":"29","author":"Pfister","year":"2018","journal-title":"Hum. Gene. Ther."},{"key":"B62","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1212\/WNL.0000000000004844","article-title":"MicroRNAs in CSF as prodromal biomarkers for Huntington disease in the PREDICT-HD study.","volume":"90","author":"Reed","year":"2018","journal-title":"Neurology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.mcn.2017.12.009","article-title":"Perturbations in the p53\/miR-34a\/SIRT1 pathway in the R6\/2 Huntington\u2019s disease model.","volume":"88","author":"Reynolds","year":"2018","journal-title":"Mol. Cell Neurosci."},{"key":"B64","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/jhd-180292","article-title":"A fresh look at huntingtin mRNA processing in huntington\u2019s disease.","volume":"7","author":"Romo","year":"2018","journal-title":"J. Huntingtons Dis."},{"key":"B65","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","article-title":"Huntington disease: natural history, biomarkers and prospects for therapeutics.","volume":"10","author":"Ross","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/s1474-4422(20)30143-5","article-title":"Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington\u2019s disease Young Adult Study (HD-YAS): a cross-sectional analysis.","volume":"19","author":"Scahill","year":"2020","journal-title":"Lancet. Neurol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jns.2018.10.024","article-title":"Leukocyte telomere shortening in Huntington\u2019s disease.","volume":"396","author":"Scarabino","year":"2019","journal-title":"J. Neurol. Sci."},{"key":"B68","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40263-019-00695-3","article-title":"Recent advances in the treatment of huntington\u2019s disease: Targeting DNA and RNA.","volume":"34","author":"Shannon","year":"2020","journal-title":"CNS Drugs"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1056\/nejmc1910544","article-title":"Targeting Huntingtin in patients with huntington\u2019s disease.","volume":"381","author":"Sheikh","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.4161\/rna.8.6.16035","article-title":"Micro RNA -214,-150,-146a and-125b target Huntingtin gene.","volume":"8","author":"Sinha","year":"2011","journal-title":"RNA Biol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.bbrc.2010.05.007","article-title":"Altered microRNAs in STHdh(Q111)\/Hdh(Q111) cells: miR-146a targets TBP.","volume":"396","author":"Sinha","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B72","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s12017-012-8183-0","article-title":"Mechanism(s) of alteration of micro RNA expressions in Huntington\u2019s disease and their possible contributions to the observed cellular and molecular dysfunctions in the disease.","volume":"14","author":"Sinha","year":"2012","journal-title":"Neuromolecular. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/jnc.14723","article-title":"Alterations in synaptic function and plasticity in Huntington disease.","volume":"150","author":"Smith-Dijak","year":"2019","journal-title":"J. Neurochem."},{"key":"B74","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/jnc.12090","article-title":"Dysregulation of REST-regulated coding and non-coding RNAs in a cellular model of Huntington\u2019s disease.","volume":"124","author":"Soldati","year":"2013","journal-title":"J. Neurochem."},{"key":"B75","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","article-title":"AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in huntington disease mouse models.","volume":"13","author":"Spronck","year":"2019","journal-title":"Mol. Ther. Methods. Clin. Dev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3390\/brainsci11020129","article-title":"Intrastriatal Administration of AAV5-miHTT in non-human primates and rats is well tolerated and results in mihtt transgene expression in key areas of huntington disease pathology.","volume":"11","author":"Spronck","year":"2021","journal-title":"Brain Sci."},{"key":"B77","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2019.01.039","article-title":"Huntingtin lowering strategies for disease modification in huntington\u2019s disease.","volume":"101","author":"Tabrizi","year":"2019","journal-title":"Neuron"},{"key":"B78","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/2211536607666180827111633","article-title":"MiRNAs: biology. Biogenesis, their Web-based Tools, and Databases.","volume":"8","author":"Tafrihi","year":"2019","journal-title":"Microrna"},{"key":"B79","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.2174\/0929867326666190621101909","article-title":"Reviewing the biochemical implications of normal and mutated huntingtin in Huntington\u2019s disease.","volume":"27","author":"Tellone","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"B80","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.brainresbull.2006.10.023","article-title":"Predictive testing for Huntington\u2019s disease.","volume":"72","author":"Tibben","year":"2007","journal-title":"Brain Res. Bull."},{"key":"B81","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/jhd-170245","article-title":"Fifteen years of clinical trials in huntington\u2019s disease: a very low clinical drug development success rate.","volume":"6","author":"Travessa","year":"2017","journal-title":"J. Huntingtons Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"eabb8920","DOI":"10.1126\/scitranslmed.abb8920","article-title":"Widespread and sustained target engagement in Huntington\u2019s disease minipigs upon intrastriatal microRNA-based gene therapy.","volume":"13","author":"Vall\u00e8s","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.neurobiolaging.2013.10.082","article-title":"Epigenetically regulated microRNAs in Alzheimer\u2019s disease.","volume":"35","author":"Van Den Hove","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"B84","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease.","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/jnc.14853","article-title":"The pathobiology of perturbed mutant huntingtin protein-protein interactions in Huntington\u2019s disease.","volume":"151","author":"Wanker","year":"2019","journal-title":"J. Neurochem."},{"key":"B86","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ab.2009.08.001","article-title":"Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington\u2019s disease.","volume":"395","author":"Weiss","year":"2009","journal-title":"Anal. Biochem."},{"key":"B87","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1172\/jci64565","article-title":"Mutant huntingtin fragmentation in immune cells tracks Huntington\u2019s disease progression.","volume":"122","author":"Weiss","year":"2012","journal-title":"J. Clin. Invest."},{"key":"B88","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/s1474-4422(17)30280-6","article-title":"Therapies targeting DNA and RNA in Huntington\u2019s disease.","volume":"16","author":"Wild","year":"2017","journal-title":"Lancet. Neurol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.cell.2013.04.003","article-title":"The long and short of microRNA.","volume":"153","author":"Yates","year":"2013","journal-title":"Cell"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/9783527678679.dg07570","article-title":"The MicroRNA.","volume":"1733","author":"Ying","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"585432","DOI":"10.3389\/fnins.2020.585432","article-title":"microRNA-based biomarkers in alzheimer\u2019s disease (AD).","volume":"14","author":"Zhao","year":"2020","journal-title":"Front. Neurosci."}],"container-title":["Frontiers in Cellular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fncel.2021.705348\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T03:56:30Z","timestamp":1628222190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fncel.2021.705348\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,6]]},"references-count":91,"alternative-id":["10.3389\/fncel.2021.705348"],"URL":"https:\/\/doi.org\/10.3389\/fncel.2021.705348","relation":{},"ISSN":["1662-5102"],"issn-type":[{"value":"1662-5102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,6]]},"article-number":"705348"}}